ADLINE CHEM LAB LIMITED is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1 | 0 | 0 | 0 | 0 |
| EBITDA (ex other income) | 1 | (5) | (0) | (0) | (0) |
| margin % | 114.7 | — | — | — | — |
| Owners' profit | 1 | (4) | (0) | (0) | (0) |
| EPS, as reported (₹) | 1.23 | (7.24) | (0.25) | 0.02 | 0.48 |
| ROE % · ROCE % | 27.1 · 24.6 | 270.1 · 331.7 | 8.6 · 10.1 | 8.9 · (124.2) | 15.8 · (271.4) |
| Debt / equity (x) | 0.50 | (0.82) | (0.87) | (1.00) | (1.02) |
| Cash from operations | 0 | 0 | (0) | (0) | (0) |
| Capex | 0 | 0 | 0 | 0 | 0 |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | (0) | (0) | 0 | (0) | (0) | (0) | (0) | 0 |
| Net profit | (0) | (0) | 0 | (0) | (0) | (0) | (0) | 0 |
| EPS (₹) | (0.02) | (0.02) | 0.04 | 0.01 | 0.01 | 0.01 | 0.17 | 0.07 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 4 Sept 2026 · Newspaper publication of AGM notice, e-voting and record date details | compliance | minimal | — | — |
| 3 Sept 2026 · 38th AGM notice and Annual Report submission for FY 2025-26 | board shareholder meetings | low | — | — |
| 3 Sept 2026 · Adline Chem Lab 38th AGM notice set for September 28, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Auditor resigns over fee dispute; new auditor appointed for 5-year term | management changes | high | — | — |
| 27 Aug 2026 · Board approves 38th AGM notice, appoints independent director, notes BSE fine | board shareholder meetings | low | — | — |
| 24 Aug 2026 · Board meeting on Aug 27 for 38th AGM notice and new independent director | board shareholder meetings | low | — | — |
| 10 Aug 2026 · Board meeting on 13 Aug to approve Q1 FY27 results | results | low | — | — |
| 15 Jul 2026 · RTA confirmation certificate for quarter ended June 30, 2026 | compliance | minimal | — | — |
| 29 Jun 2026 · Trading Window Closure Ahead of Q1 FY27 Financial Results | compliance | minimal | — | — |
| 30 May 2026 · Enclosed | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 44.3 | 28.9 | 121 of 169 | 29% |
| ROCE | (613.1) | 10.8 | 182 of 183 | 1% |
| ROE | 15.8 | 10.4 | 44 of 171 | 75% |
| Debt / Equity | (1.0) | 0.1 | 5 of 171 | 98% |
| Profit growth | 178.2 | 30.9 | 27 of 158 | 83% |
| Market cap | 7 | 839 | 178 of 182 | 2% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
